Japan still need to review Pfizer’s COVID-19 vaccines
Japan still need to review Pfizer’s COVID-19 vaccines. Japanese media: Japan will receive Pfizer vaccine as soon as March next year, and safety data still needs to be reviewed.
The COVID-19 vaccine jointly developed by the US pharmaceutical company Pfizer and the German company BioNTech has been vaccinated in the UK on the 8th. Pfizer has also reached a basic agreement with the Japanese government on the supply of 120 million doses (60 million doses) of vaccines in the first half of next year. However, it needs to go through clinical trials and review procedures in Japan. It is expected that vaccination will begin around March next year at the earliest.
According to a report from Kyodo News on December 9, the Japanese government stated that to allow a COVID-19 vaccine to be vaccinated in China, not only overseas data is required, but it is also necessary to submit domestic clinical trial results and conduct review. Pfizer is currently conducting Phase I and Phase II clinical trials in Japan, which is equivalent to the initial phase of a three-phase clinical trial.
Among several other world-leading vaccines, the British pharmaceutical giant AstraZeneca has also reached an agreement with the Japanese government to provide 120 million doses of the vaccine, and is undergoing domestic clinical trials. It is reported that Moderna, an American biotechnology company, has also signed a contract with the Japanese government to provide 50 million doses of vaccines, but clinical trials are still in the preparation stage.
Among Japanese domestic manufacturers, “AnGes”, a pharmaceutical innovation company located in Ibaraki City, Osaka Prefecture, has started Phase 2 and Phase 3 trials that are equivalent to the next phase of Phase 1 and Phase 2 clinical trials. Other companies such as Shiono Yoshi Pharmaceutical, located in Osaka City, also plan to start trials in the near future.
Many of the vaccines under development use new technologies that have not been put into practical use in the past. Yasuo Hiroshi, Director of the Primate Science Research Center of the National Institute of Medical Science, Health and Nutrition, Japan, said that “it is important to pay attention to the situation in the countries that first approved the use of the vaccine”, such as whether the vaccinators experience pain and immune abnormalities after vaccination. .